Yiling Pharmaceuticals fell by the limit today!
Today, the market fluctuated and adjusted throughout the day, with the Shanghai Composite Index barely holding on to 3,100 points. As of the close, the Shanghai Composite Index fell by 1.92, the Shenzhen Composite Index fell by 1.51, the GEM Index fell by 1.14, and northbound funds sold a net 1.491 billion yuan throughout the day. Below, the editor brings you Yiling Pharmaceutical's daily limit today. I hope you like it.
Yiling Pharmaceuticals fell by the limit today
On the market, pharmaceuticals and biology led the decline, with finance, consumption, and infrastructure leading the decline; online education and lithium mining themes bucked the trend and strengthened.
At noon today, the "Nanjing Release" public announced that in accordance with the requirements of the municipal government and in order to alleviate the recent difficulty in purchasing antipyretics, Nanjing will continue to release 2 million antipyretic drugs on the market every day starting from today. Starting from December 19, 153 retail pharmacies will sell the medicine in pieces. Each customer is limited to 6 pills, which can be purchased with medical insurance.
The pharmaceutical sector has cooled down sharply today, with previously hotly speculated concept stocks such as COVID-19 treatment and ursodeoxycholic acid all falling. Among them, Yiling Pharmaceutical and Zhongsheng Pharmaceutical both fell by the limit. Northeast Pharmaceutical, the pharmaceutical company behind "2 yuan for 20 tablets of antipyretic medicine," received strong support from investors and hit the daily limit. Xinhua Pharmaceutical, the "leader of ibuprofen," hit a new record high in early trading and then fell back. .
Ruyi Group, the leader of "anti-viral fabrics" known as "China LV", hit the daily limit shortly after the opening, and then quickly fell to the lower limit, and a "heaven and earth floor" was staged during the session.
The COVID-19 treatment sector failed to perform well, and Yiling Pharmaceutical fell by the limit
Today, the pharmaceutical sector fell across the board, with a limit-down trend set off in late trading. Yiling Pharmaceutical, Zhongsheng Pharmaceutical, Teyi Pharmaceutical, Tailong Pharmaceutical, Guizhou Bailing and other stocks fell to the limit.
In terms of news, there are recent rumors on the Internet that Lianhua Qingwen can cause liver damage and liver failure. In early trading today, Yiling Pharmaceuticals opened sharply and hit its daily limit in the afternoon. As of the close, Yiling Pharmaceutical's price was 40.67 yuan per share, with a full-day turnover of 5.5 billion yuan, and the latest market value was less than 70 billion yuan.
In this regard, Yiling Pharmaceutical issued a statement on the safety of Lianhua Qingwen on the 18th: Lianhua Qingwen is based on the prescription history, systemic toxicology, clinical research and meta-analysis, and post-marketing studies. Adverse reaction monitoring and other aspects among large-scale populations have confirmed its good safety. Lianhua Qingwen's drug instructions clearly reflect adverse reactions. Relevant media and individuals have fabricated and spread "Lianhua Qingwen can cause liver damage and liver failure" - false facts, false statements and malicious defamation of the goodwill of our company and products, which have seriously infringed on our rights and interests. Our company reserves the right to use legal means The right to safeguard one's own legitimate rights and interests.
CITIC Construction Investment expects that starting from the second quarter of 2023, the medical system will gradually adapt to the new normal, superimposing the low base in the same period last year, and the volume of medical terminal diagnosis and treatment will recover better. From the perspective of retail terminals, the recovery of passenger flow after the optimization of epidemic prevention policies, the demand for self-diagnosis and treatment under the background of the "influenza" of the new coronavirus, and the weakening of early negative factors will promote the industry to achieve better growth next year.
Pharmaceutical companies behind "20 yuan for 20 antipyretic pills" are on fire
Recently, some netizens posted a video saying that the antipyretic acetaminophen tablets sold by Northeast Pharmaceutical and Northeast Pharmacy, Each board sells for 2 yuan. Related topics once became hot searches on Weibo, further boosting the company's stock price.
In early trading today, Northeast Pharmaceutical opened above the daily limit, with nearly 1.3 million orders closed. As of the close, Northeast Pharmaceutical reported 7.76 yuan per share, and the latest total market value was 11.13 billion yuan.
Northeast Pharmaceuticals responded that it has worked overtime to produce acetaminophen tablets and other medicines to treat fevers and colds, and sell them at affordable prices in pharmacies. At noon on December 16, relevant people from Northeast Pharmaceutical Company stated that the company is fully organizing production and can supply 300 pieces to pharmacies in Shenyang area every day. There are more than 100 drugstore chain stores in Northeast Shenyang, all of which sell at low prices. All pharmacies sell acetaminophen tablets at 2 yuan per plate.
The data from the Dragon and Tiger list shows that the stock has been on the Dragon list twice in the past 5 days due to the cumulative increase deviation value reaching 20, the daily decline deviation value reaching 7, and the daily amplitude value reaching 15 in three consecutive trading days. Tiger list.
From a performance perspective, Northeast Pharmaceutical achieved operating income of 6.569 billion yuan in the first three quarters of this year, a year-on-year increase of 7.60%; net profit attributable to the parent company was 128 million yuan, a year-on-year increase of 40.255%.
Minsheng Securities believes that the significant adjustments in epidemic prevention and control policies in various places have led to a rush to buy cold medicines, especially antipyretic and analgesic medicines, in most cities across the country. Since my country is a major producer of antipyretic and analgesic medicines, Production capacity far exceeds domestic demand, and the short-term mismatch between supply and demand will soon be alleviated, strongly supporting a rapid recovery after the epidemic.
"China LV" staged a "heaven and earth floor" during the session
In early trading today, Ruyi Group, the leader in "anti-viral fabrics", hit the daily limit shortly after the opening, and then quickly fell to the lower limit. A "heaven floor" was staged at one point. As of the close, Ruyi Group rose by 1.65.
Since December 2, Ruyi Group, known as "China LV", has started a rising market. It has achieved 8 daily limits in 12 trading days, and its stock price has doubled, with the cumulative increase in the range reaching 109.27.
Public information shows that Ruyi Group’s main business includes the design, production and sales of textiles, clothing and apparel. Recently, the concept of antibacterial and antiviral fabrics has received close attention and crazy speculation from investors. Ruyi Group has also been enthusiastically sought after by the market. Its stock price has continued to skyrocket and it has been on the Dragon and Tiger List many times.
On the evening of December 18, Ruyi Group issued a change announcement stating that as of now, the "Development and Research of Antibacterial and Antiviral Machine Washable Wool Worsted Fabrics" project is in the pilot stage and has not yet formed mass production. Its application and market prospects need to be further clarified. The antiviral and antibacterial effects need to be tested by the market. There is still uncertainty in the market's recognition and acceptance of this technology. There is also uncertainty in the future economic benefits and the impact on the company's performance.
According to the research report of Soochow Securities, consumers are increasingly paying attention to the application of new anti-viral and anti-bacterial technologies in textiles, and textile companies are also constantly strengthening the research and development of anti-viral and anti-bacterial functional textiles. Currently, 31 listed companies have deployed antiviral and antibacterial patents and products.
Education stocks are active against the trend
Guangzheng Education rose more than 50%
Today, the education sector led the gains in the two cities. As of the close, Onli Education hit the daily limit, and Dou Shen Education rose by more than 10%, followed by Quantong Education, Mejim Education, Chuanzhi Education, etc.
The Hong Kong stock education sector has performed even stronger. As of press time, Guangzheng Education has risen by more than 50%, and Chengshi Foreign Education has risen by more than 20%. Jiahong Education, New Higher Education Group, Hope Education, and Lide Education are among the top gainers.
In terms of news, the "Outline of the Strategic Plan for Expanding Domestic Demand (2022-2035)" (hereinafter referred to as the "Outline") recently issued by the Central Committee of the Communist Party of China and the State Council was released on December 14. On the 15th, the National Development and Reform Commission released the "Implementation Plan for the Strategy to Expand Domestic Demand during the 14th Five-Year Plan".
In the third part of the "Outline", "comprehensively promote consumption and accelerate the improvement and upgrading of consumption", Article 9, "Actively develop service consumption", reiterates "support and standardize the development of private education".
Huatai Securities believes that the "Outline" further clarifies its support for private education, which will help alleviate market concerns about the decapitalization of education and the difficulty in implementing for-profit registration in the private higher education sector.